Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Study of HTD4010 in Healthy Volunteers and T2DM Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: HTD4010
Sponsor:   HighTide Biopharma Pty Ltd
Not yet recruiting - verified September 2015

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Diabetes Mellitus, Type 2
Interventions:   Drug: Biphasic Remogliflozin Etabonate;   Other: Placebo
Sponsors:   BHV Pharma;   Integrium
Recruiting - verified August 2015

A Study to Assess the Safety and Efficacy of the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin (MK-0431-838)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Matching placebo to sitagliptin;   Drug: Matching placebo to dapagliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting - verified August 2015

Sitagliptin Therapy and Kinetics of Inflammatory Markers

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo
Sponsors:   Laval University;   Merck Sharp & Dohme Corp.
Completed - verified August 2015

Lifestyle-Related Health Outcomes in Prediabetes and Diabetes

Conditions:   Obesity;   Prediabetic State;   Type 2 Diabetes
Interventions:   Behavioral: Health Education and Coaching Strategy;   Behavioral: Dietary consult
Sponsors:   Indiana University;   Purdue University
Recruiting - verified August 2015

Tofogliflozin GLP-1 Analogue Combination Trial

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tofogliflozin;   Drug: GLP-1 analogue
Sponsors:   Kowa Company, Ltd.;   Sanofi
Recruiting - verified August 2015

Adipose Tissue Imaging in Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Radiation: 18F-FDG PET/CT;   Device: euglycemic clamp;   Device: hypoglycemic clamp
Sponsor:   Radboud University
Recruiting - verified August 2015

Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 Treatment

Condition:   GLP-1;Telomere-telomerase System; Par-4
Intervention:   Drug: Liraglutide
Sponsor:   Third Military Medical University
Recruiting - verified August 2015

Psychoneuroimmunology Therapy in Uncontrolled Diabetic Patients: A Quasi-experimental Study

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: psychoneuroimmune therapy;   Drug: Conventional treatment
Sponsors:   Fundación Salutia;   Coomeva E.P.S;   Sinergia
Not yet recruiting - verified August 2015

A 12/24-weeks Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:   Biological: Bydureon
Sponsor:   AstraZeneca
Not yet recruiting - verified August 2015

Modulating Effects of Oil Palm Phenolics in Uncontrolled Insulin-treated Type 2 Diabetes Mellitus

Condition:   Uncontrolled Insulin-treated Type 2 Diabetes Mellitus
Intervention:   Dietary Supplement: Oil Palm Phenolics
Sponsors:   University of Science Malaysia;   Malaysia Palm Oil Board;   Clinical Research Centre, Malaysia
Not yet recruiting - verified August 2015

Improving Adherence and Commitment to Treatment in Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Behavioral: medical team;   Behavioral: peers group;   Behavioral: SMS notification
Sponsor:   Clalit Health Services
Not yet recruiting - verified August 2015

Human Intestinal Peptides Evaluation and Research

Conditions:   Obesity;   Diabetes Mellitus, Type 2
Intervention:   Other: blood sample analysis
Sponsor:   Turkish Metabolic Surgery Foundation
Enrolling by invitation - verified August 2015

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2015

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Conditions:   Essential Hypertension;   Type 2 Diabetes Mellitus
Intervention:   Drug: Azilsartan Medoxomil
Sponsor:   Takeda
Recruiting - verified August 2015

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Conditions:   Type 2 Diabetes Mellitus,;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Glimepiride;   Drug: Placebo for dapagliflozin;   Drug: Placebo for saxagliptin;   Drug: Placebo for glimepiride
Sponsor:   AstraZeneca
Not yet recruiting - verified August 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified August 2015

Processed Meat and Brain Regions Related to Reward and Addiction

Condition:   Type 2 Diabetes
Interventions:   Other: Processed meat hamburger;   Other: Vegan sandwich
Sponsor:   Institute for Clinical and Experimental Medicine
Not yet recruiting - verified August 2015

Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: 2 capsules of allopurinol 150 mg daily for 3 month;   Drug: 2 capsules of lactose daily for 3 month
Sponsor:   Hospices Civils de Lyon
Recruiting - verified August 2015

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified August 2015

Daily Physical Activity After Meals -Long Term Effects on Blood Glucose

Conditions:   Blood Glucose;   Blood Glucose Related Variables
Intervention:   Behavioral: Postprandial physical activity
Sponsors:   Lillehammer University College;   University of Oslo
Completed - verified August 2015

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: KD026;   Drug: Placebo;   Drug: Metformin
Sponsor:   Kadmon Corporation, LLC
Recruiting - verified August 2015

TAK-648 in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: TAK-648;   Drug: Placebo
Sponsor:   Takeda
Active, not recruiting - verified August 2015

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Low Metformin;   Drug: Mid Metformin;   Drug: High Metformin;   Drug: Metformin
Sponsor:   NuSirt Biopharma
Active, not recruiting - verified August 2015

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE (U300)
Sponsor:   Sanofi
Recruiting - verified August 2015

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

Condition:   Diabetic Nephropathy
Interventions:   Drug: MLN1202 Placebo;   Drug: MLN1202
Sponsor:   Takeda
Not yet recruiting - verified August 2015

Multiple Ascending Dose Study in Healthy Male Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR425899;   Drug: placebo
Sponsor:   Sanofi
Recruiting - verified August 2015

Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Momordica charantia;   Drug: Placebo
Sponsor:   University of Guadalajara
Recruiting - verified August 2015

Effect of Exercise Frequency on Metabolic Control and Heart Function in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: accumulated exercise;   Behavioral: traditional exercise
Sponsor:   Norwegian University of Science and Technology
Recruiting - verified August 2015

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GLWL-01, Part A;   Drug: Placebo, Part A;   Drug: GLWL-01, Part B;   Drug: Placebo, Part B;   Drug: GLWL-01, Part C;   Drug: Placebo, Part C
Sponsor:   GLWL Research Inc.
Recruiting - verified August 2015

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: ASP8232;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Recruiting - verified August 2015

Mechanisms of Weight Loss With SGLT2 Inhibition

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2015

A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Conditions:   Diabetes Mellitus;   Diabetes Mellitus Complications;   Gastroparesis
Interventions:   Drug: RM-131;   Drug: Placebo
Sponsor:   Rhythm Pharmaceuticals, Inc.
Recruiting - verified September 2015

Effects of Fruit Extracts on Glycaemia: The GLU-FRU Study

Condition:   Postprandial Hyperglycemia
Intervention:   Dietary Supplement: Polyphenols
Sponsor:   King's College London
Completed - verified August 2015

Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

Conditions:   Dipeptidyl-Peptidase 4 Inhibitors;   LDL Cholesterol;   Glycosylated Hemoglobin;   Diabetes Mellitus;   Coronary Disease
Interventions:   Drug: Anagliptin;   Drug: Sitagliptin
Sponsor:   Institute for Clinical Effectiveness, Japan
Recruiting - verified August 2015

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD

Conditions:   Prediabetic State;   Non-alcoholic Fatty Liver Disease;   Type 2 Diabetes Mellitus
Interventions:   Drug: Cenicriviroc 150 mg;   Drug: Matching placebo
Sponsor:   Tobira Therapeutics, Inc.
Enrolling by invitation - verified August 2015

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified August 2015

Patient Experiences With Injection Needles

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: Subcutaneous insertions of needles
Sponsors:   University of Copenhagen;   Novo Nordisk A/S
Completed - verified August 2015

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified August 2015

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

Conditions:   Overweight;   Obesity
Interventions:   Device: Gelesis100;   Device: placebo
Sponsor:   Gelesis, Inc.
Recruiting - verified August 2015

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2963016;   Drug: LANTUS®;   Drug: Oral Antihyperglycemic Medication
Sponsors:   Eli Lilly and Company;   Boehringer Ingelheim
Recruiting - verified August 2015

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR342434;   Drug: insulin lispro;   Drug: insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified August 2015

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: LIXISENATIDE AVE0010;   Drug: metformin
Sponsor:   Sanofi
Completed - verified August 2015

Sitagliptin and Glucagon Counterregulation

Condition:   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Placebo
Sponsors:   Lund University;   Merck Sharp & Dohme Corp.
Recruiting - verified October 2014

Adult Accuracy Study of the Enlite 3 Glucose Sensor

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Interventions:   Device: Enlite 3;   Device: Guardian Mobile App;   Device: 640G Insulin Pump
Sponsor:   Medtronic Diabetes
Active, not recruiting - verified August 2015

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Exenatide;   Drug: Exenatide matching placebo
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Sitagliptin;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Sitagliptin;   Drug: Glimepiride
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2015

Phase 3 28 Week Study and 24 Week Extension to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Condition:   Diabetes Mellitus
Interventions:   Drug: Exantide with Dapagliflozin;   Drug: Exentide;   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified August 2015

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified August 2015

Telemedicine Strategy With Home Treatment Save Resources

Condition:   Type 2 Diabetes Mellitus
Interventions:   Device: A videotelephone, TandBerg E20,;   Behavioral: Behavioral motivation
Sponsor:   Kolding Sygehus
Completed - verified August 2015

A Study of Once-Daily RO6811135 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Placebo QD;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Recruiting - verified September 2015

Transformation of Indigenous Primary Healthcare Delivery

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   Lawson Health Research Institute;   Canadian Institutes of Health Research  (CIHR);   University of Western Ontario, Canada;   First Nation Community Partners;   Health Canada;   First Nations and Inuit Health Branch;   Assembly of First Nations;   Canadian Diabetes Association;   Ontario Stroke Network;   Heart and Stroke Foundation of Canada;   Toronto Health Economics and Technology Assessment Collaborative;   Tri-Ethnic Research Center Colorado State University;   Hindsight Healthcare Strategies ;   AstraZeneca
Recruiting - verified August 2015

Study of the Mechanisms of Metabolic Adaptations to Overfeeding

Conditions:   Obesity;   Diabetes
Interventions:   Other: Hypercaloric diet;   Dietary Supplement: polyphenols;   Dietary Supplement: placebo (for polyphenols)
Sponsors:   Centre Hospitalier Universitaire Vaudois;   University of Lyon
Recruiting - verified August 2015

Physician Led Counseling in Management of Depression in Type 2 Diabetes Mellitus

Conditions:   Depression;   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Physician Supported Care;   Other: Usual care
Sponsors:   Adwin Life Care;   Warwick Research Services 
Active, not recruiting - verified September 2015

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Low Metformin;   Drug: Metformin;   Drug: Mid Metformin;   Drug: High Metformin
Sponsor:   NuSirt Biopharma
Active, not recruiting - verified April 2015

Novel Model for South Asian Treatment in Diabetes (NaMaSTe-Diabetes) Trial in Primary Care

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Culturally tailored diabetes program
Sponsors:   University of British Columbia;   Canadian Institutes of Health Research  (CIHR)
Recruiting - verified August 2015

Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Matching Placebo to Ertugliflozin 5 mg;   Drug: Matching Placebo to Ertugliflozin 10 mg;   Drug: Matching Placebo to sitagliptin 100 mg;   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Sitagliptin 100 mg;   Drug: Metformin >= 1500 mg/day;   Biological: Insulin Glargine Rescue Medication;   Drug: Glimepiride Rescue Medication
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2015

DPP-4 Inhibition, Incretins and Islet Function

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Vildagliptin;   Drug: Sitagliptin
Sponsor:   Lund University
Recruiting - verified March 2015

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Condition:   Essential Hypertension Complicated by Type 2 Diabetes Mellitus
Interventions:   Drug: Azilsartan;   Drug: Telmisartan
Sponsor:   Takeda
Recruiting - verified August 2015

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified August 2015

An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms

Conditions:   Prediabetes;   Diabetes Type 1;   Diabetes Type 2
Intervention:  
Sponsor:   Profil Institut für Stoffwechselforschung GmbH
Not yet recruiting - verified September 2015

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (15 mg);   Drug: Placebo;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Glimepiride;   Biological: Insulin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2015

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified August 2015

Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE;   Drug: Metformin;   Drug: DPP-4 inhibitor;   Drug: Sulphonylurea
Sponsor:   Sanofi
Completed - verified August 2015

The Swedish Study on Paleolithic Diet for Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Paleolithic diet;   Behavioral: Diabetes diet
Sponsors:   Lund University Hospital;   Region Skane
Active, not recruiting - verified August 2015

Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes

Conditions:   Prediabetes;   Gestational Diabetes Mellitus;   Obesity
Interventions:   Behavioral: Weight Watchers;   Behavioral: National Diabetes Education Program
Sponsors:   Indiana University;   Weight Watchers International;   Indiana Clinical and Translational Sciences Institute;   National Diabetes Education Program
Active, not recruiting - verified August 2015

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 50 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified August 2015

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2015

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

Condition:   Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Liraglutide;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified June 2015

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (10 mg);   Drug: Placebo to Ertuglifozin;   Drug: Metformin;   Drug: Placebo to Metformin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2015

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Cardiovascular Disease
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Placebo;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Merck Sharp & Dohme Corp.
Recruiting - verified August 2015

A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Withdrawn - verified September 2015

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"

Condition:   Patients With Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution
Intervention:   Drug: Alogliptin
Sponsor:   Takeda
Active, not recruiting - verified August 2015

Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

Conditions:   Obesity;   Diabetes
Interventions:   Drug: BYETTA treatment;   Drug: Metformine
Sponsor:   Assistance Publique Hopitaux De Marseille
Completed - verified August 2015

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

PMS of Trazenta on the Long-term Use as Add-on Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified September 2015

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: Subetta;   Drug: Placebo
Sponsor:   Materia Medica Holding
Recruiting - verified August 2015

Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals

Condition:   Obesity
Intervention:   Drug: Roflumilast
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Suspended - verified August 2015

Encourage Healthy Families

Conditions:   Gestational Diabetes Mellitus;   Pre-diabetes
Intervention:   Behavioral: Diabetes Prevention Program (DPP)
Sponsors:   Indiana University;   The JPB Foundation;   The YMCA of Greater Indianapolis;   Regenstrief Institute, Inc.;   Indiana Clinical and Translational Sciences Institute
Active, not recruiting - verified August 2015

Study of Procoagulation Markers in Stroke Patients

Conditions:   Stroke;   Hyperglycemia;   Procoagulation Markers
Intervention:   Other: Glycemic Control
Sponsors:   Temple University;   National Institute of Neurological Disorders and Stroke (NINDS);   Neurological Emergencies Treatment Trials Network (NETT);   University of Virginia;   University of Michigan;   Medical University of South Carolina;   Georgia Regents University
Recruiting - verified August 2015

A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Albiglutide + SU;   Drug: Albiglutide + biguanide;   Drug: Albiglutide + glinide;   Drug: Albiglutide + TZD;   Drug: Albiglutide + alpha-glucosidase inhibitor
Sponsor:   GlaxoSmithKline
Completed - verified August 2015

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2015

Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users

Condition:   DIABETES Mellitus Type 2 Not Well Controlled
Interventions:   Drug: Liraglutide;   Drug: Sitagliptin
Sponsor:   Anna Cruceta
Completed - verified September 2014

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Glimepiride;   Drug: Matching placebo to glimepiride;   Drug: Insulin glargine;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified August 2015

Korean Post-marketing Surveillance for Kombiglyze XR®

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Bristol-Myers Squibb
Recruiting - verified August 2015

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2015

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance.

Conditions:   Diabetes;   Cardiovascular Disease
Interventions:   Other: Uncontrolled nutritional intervention with a supplemental beverage;   Other: Placebo
Sponsors:   Laval University;   Consortium de recherche et innovations en bioprocédés industriels au Québec (CRIBIQ);   Institute of Nutraceutical and Functional Foods (INAF)
Completed - verified September 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Condition:   Non-Alcoholic Steatohepatitis (NASH)
Interventions:   Drug: GFT505 80mg;   Drug: GFT505 120mg;   Drug: Placebo
Sponsors:   Genfit;   Naturalpha;   Premier Research Group plc
Active, not recruiting - verified August 2015

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

PREterM FOrmula Or Donor Breast Milk for Premature Babies

Conditions:   Adiposity;   Insulin Resistance;   Metabolomic Profile;   microRNA Profile
Interventions:   Other: Unfortified Human donor Milk used to make up any shortfall in mother's own milk;   Other: Fortified Human donor Milk used to make up any shortfall in mother's own milk;   Other: Preterm Formula used when there is a shortfall in mother's own milk
Sponsor:   Imperial College London
Recruiting - verified August 2015

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: OAD;   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified August 2015

Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Peer Mentoring
Sponsor:   Department of Veterans Affairs
Recruiting - verified August 2015

Stress Management Among Latinos With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: stress management
Sponsors:   Yale University;   Hartford Hospital;   University of Connecticut Health Center;   Hispanic Health Council
Completed - verified August 2015

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952;   Drug: RO6807952;   Drug: liraglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified September 2015

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2015

A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: lisinopril;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Oxyntomodulin;   Drug: Liraglutide 0.6 mg;   Drug: Liraglutide 1.2 mg;   Drug: Placebo for Oxyntomodulin;   Drug: Placebo for Liraglutide
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified September 2015

A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)

Condition:   Anemia
Intervention:  
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13)

Conditions:   Diabetes;   Depression
Interventions:   Other: Psychiatrist Interview;   Other: Depression screening - control
Sponsors:   Chinese University of Hong Kong;   Asia Diabetes Foundation
Completed - verified August 2015

JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Janumet, Lantus;   Drug: metformin, gliclazide, protaphane
Sponsor:   Chinese University of Hong Kong
Completed - verified August 2015

Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified August 2015

Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: Sitagliptin phosphate;   Drug: Comparator: Sulfonylurea;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified September 2015

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: pioglitazone
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: RO5095932;   Drug: RO5095932
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin/Metformin FDC;   Drug: Comparator: Glimepiride;   Drug: Matching placebo to Sitagliptin/Metformin FDC;   Drug: Matching placebo to glimepiride
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Conditions:   Post Bariatricsurgery;   Hypoglycemia
Interventions:   Drug: Exendin-(9-39);   Drug: Atropine;   Drug: GLP-1 and GIP
Sponsors:   University of Cincinnati;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   David D'Alessio
Recruiting - verified September 2015

A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO5095932;   Drug: RO5095932;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

PEARL Program: Empowerment Program for Patients With Type 2 Diabetes (HK4)

Condition:   Diabetes
Interventions:   Behavioral: Patient Peer Support and Empowerment;   Behavioral: Usual Care
Sponsors:   Chinese University of Hong Kong;   Asia Diabetes Foundation
Completed - verified August 2015

A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK6349;   Drug: Comparator: Placebo to MK6349
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified August 2015

A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency

Conditions:   Type 2 Diabetes;   Renal Insufficiency
Interventions:   Drug: Glargine & glulisine;   Drug: Glargine & glulisine
Sponsors:   Loyola University;   Sanofi
Completed - verified August 2015

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: pioglitazone;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: sitagliptin phosphate;   Drug: Comparator: metformin;   Drug: Comparator: metformin;   Drug: Comparator: Antidiabetic Standard of Care
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO5027838;   Drug: RO5027838;   Drug: RO5093151;   Drug: RO5093151
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Taspoglutide in Type 2 Diabetic Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: metformin;   Drug: pioglitazone;   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: exenatide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

The Joint Asia Diabetes Evaluation (JADE) Program in Hong Kong Community

Condition:   Type 2 Diabetes Mellitus
Intervention:   Other: Protocol-driven care under JADE Program
Sponsors:   Chinese University of Hong Kong;   Asia Diabetes Foundation
Completed - verified August 2015

Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial

Conditions:   Type 2 Diabetes Mellitus;   Cardiovascular Disease
Interventions:   Drug: add-on pioglitazone;   Drug: add-on sulphonylurea
Sponsors:   Italian Society of Diabetology;   Associazione Medici Diabetologi (AMD);   Associazione Nazionale Medici Cardiologi Ospedalieri
Active, not recruiting - verified August 2015

A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4998452;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Condition:   Gestational Diabetes
Interventions:   Drug: Exenatide;   Genetic: Buccal/blood Sample Collection
Sponsors:   Georgetown University;   Washington Hospital Center
Withdrawn - verified August 2015

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Comparator: Rosiglitazone;   Drug: Comparator: Placebo;   Drug: Comparator: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RG1511
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of DPP-IV (3) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4876904
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide;   Drug: sitagliptin
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified August 2015

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Glyburide
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Simvastatin
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy

Conditions:   Type 2 Diabetes Mellitus;   DM Nephropathy
Intervention:   Behavioral: Multidisciplinary team care
Sponsor:   Chinese University of Hong Kong
Completed - verified August 2015

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Metformin;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified September 2015

Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes

Conditions:   Diabetes Mellitus;   Obesity
Intervention:   Procedure: Oral glucose tolerance test
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2015

Get CardioSmart

You're Invited